Advancing Scientific Research for Rheumatic Conditions

AbbVie to present thirty-five abstracts at the 2018 ACR/ARHP Annual Meeting demonstrating an ongoing commitment to researching additional therapeutic options and advancing care for patients.

Read More

Our Journey of Impact

Come with us as we remember where we’ve been, and look forward to where we’re going.

Learn More

Latest News

If you are a member of the news media and have questions or need additional information, please contact our Communications Team.

Oct 18, 2018

AbbVie and Morphic Therapeutic Announce Collaboration Targeting Fibrotic Diseases

Oct 18, 2018

AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Fresenius Kabi

Oct 17, 2018

AbbVie Announces Supplemental New Drug Application Accepted for Priority Review by U.S. FDA for IMBRUVICA® (ibrutinib) in Combination with Obinutuzumab (GAZYVA®) for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Oct 16, 2018

AbbVie Reinforces Leadership in Gastroenterology with New Data Showcasing Research Advancements Across Robust Portfolio at United European Gastroenterology (UEG) Week 2018
Read More

You must be logged in to view this item.

This area is reserved for members of the news media. If you qualify, please update your user profile and check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.

YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

Notice

The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?